Menu

FDA Nominee Commits to Mifepristone Safety Study

1 day ago 0

The nominee for the Food and Drug Administration (FDA) commissioner, Dr. Heidi Overton, has promised to set a timeline and clear parameters for a safety study on the abortion medication mifepristone. This was announced by the office of Senator Josh Hawley, a member of the Senate Health, Education, Labor, and Pensions Committee, who has been advocating for accountability in this area.

Senator Hawley emphasized the importance of this commitment as a significant step toward securing the appropriate study and reinstating necessary safeguards on the medication. He stated that any FDA commissioner nominee must adhere to these commitments to gain his support.

The Trump administration plans to conclude a comprehensive safety study on mifepristone by March 2027. The FDA will make regulatory adjustments based on these findings no later than September 2027. These new safety protocols will apply to both the branded version of mifepristone and its generic equivalents.

The study will include data from Medicaid and other commercial sources from before and after the Biden administration lifted restrictions on the medication. The administration’s actions have faced criticism since 2023 for removing requirements for in-person doctor visits and dispensing.

The FDA has delayed its review several times, previously committing to release a study by 2025. There are concerns that the agency might be omitting essential data. Dr. Overton has stated that if confirmed, she will advocate for completing the work swiftly while ensuring a thorough review.

In March, Senator Hawley called for legislation to ban mifepristone, citing its significant danger. He stressed that Congress should address these risks due to the drug’s largely unregulated distribution and the manufacturers’ profit motives.

Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *